Allergan was blasted for its unusual Mohawk patent license, and now it's a total flop

After months of criticism that even spilled into a judge's opinion in a separate case, Allergan's Restasis patent deal with the Saint Regis Mohawk Tribe just didn't work. Thanks to a Friday ruling, the blockbuster eye drug has to face the very patent challenge Allergan sought to prevent.
Read more: https://www.fiercepharma.com/legal/allergan-s-controversial-tribal-licensing-pact-falls-short-ptab-scrutiny?source=Snapzu